KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) FCF Margin (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of FCF Margin readings, the most recent being 5.22% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 74.0% to 5.22% in Q1 2026 year-over-year; TTM through Mar 2026 was 6.76%, a 175.0% increase, with the full-year FY2025 number at 6.65%, up 212.0% from a year prior.
  • FCF Margin hit 5.22% in Q1 2026 for Teva Pharmaceutical Industries, down from 21.57% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 23.89% in Q4 2023 to a low of 7.76% in Q1 2023.
  • Median FCF Margin over the past 5 years was 3.14% (2025), compared with a mean of 5.02%.
  • Biggest five-year swings in FCF Margin: plummeted -1545bps in 2023 and later soared 1632bps in 2024.
  • Teva Pharmaceutical Industries' FCF Margin stood at 21.4% in 2022, then increased by 12bps to 23.89% in 2023, then tumbled by -36bps to 15.38% in 2024, then surged by 40bps to 21.57% in 2025, then tumbled by -124bps to 5.22% in 2026.
  • The last three reported values for FCF Margin were 5.22% (Q1 2026), 21.57% (Q4 2025), and 5.2% (Q3 2025) per Business Quant data.